Huide S. Zhu
Shantou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Cost-effectiveness analysis of toripalimab and bevacizumab versus sorafenib for advanced hepatocellular carcinoma in China.
Journal: Scientific reports
Published: January 06, 2026
Cadonilimab plus chemotherapy compared to chemotherapy as first-line treatment for persistent, recurrent, or metastatic cervical cancer in China: a cost-effectiveness analysis.
Journal: BMC health services research
Published: June 03, 2025
Toripalimab plus chemotherapy versus chemotherapy as first-line therapy for extensive-stage small cell lung cancer: a cost-effectiveness analysis.
Journal: Frontiers in immunology
Published: March 17, 2025
Cost-effectiveness analysis of adebrelimab in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer.
Journal: PloS one
Published: February 07, 2025
Camrelizumab plus rivoceranib compared sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis.
Journal: BMJ open
Published: December 11, 2024
Tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A cost-effectiveness analysis.
Journal: PloS one
Published: November 12, 2024
Design and discovery of novel heteroaryl substituted pregnenolone derivatives as potent anti-neuroinflammatory agents targeting LPS-stimulated BV-2 microglial cells.
Journal: Steroids
Published: November 10, 2024
Pembrolizumab combined with chemotherapy versus placebo combined with chemotherapy for HER2-negative advanced gastric cancer in China: a cost-effectiveness analysis.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: July 09, 2024
First-Line Tislelizumab for Advanced or Metastatic Esophageal Squamous Cell Carcinoma:A Cost-Effectiveness Analysis.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: November 30, 2023
Design, synthesis and molecular modeling of novel D-ring substituted steroidal 4,5-dihydropyrazole thiazolinone derivatives as anti-inflammatory agents by inhibition of COX-2/iNOS production and down-regulation of NF-κB/MAPKs in LPS-induced RAW264.7 macrophage cells.
Journal: European journal of medicinal chemistry
Published: November 24, 2023
Last Updated: 09/26/2026